EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
The emergence of new infections in India is a growing concern
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
Subscribe To Our Newsletter & Stay Updated
